WATCH NOW: Clinical experience with ALPROLIX

We are committed to supporting you and your patients

Information and resources for your practice

Protection, Experience, and Dosing:
 A Discussion With Dr De Angulo

Dosing Calculator

Calculate your patient's dose by weight for prophylaxis, bleed control, or surgery.

Resources for your patients

Alprolix Instructions for Use Guide

This document contains information on how to use ALPROLIX, including reconstitution, pooling, administration, and storage.

ALPROLIX Instructions for Use

ALPROLIX offers a range of financial assistance programs* for your patients

Access to these and other services is voluntary, and your patients are not obligated to begin treatment if they contact us. You and your patients make all treatment-related decisions, and most importantly, the privacy and security of their personal information are always protected.

Free Trial Plus Program
Patients can receive their first 30-day supply of ALPROLIX immediately with a valid prescription. Patients may also be able to receive free factor IX for up to 1 year, if needed.

Copay Program
For eligible patients, the ALPROLIX Copay Program can cover up to $20,000 of copayment or co-insurance costs associated with their prescription. There are no income requirements or caps.

Factor Access Program
If your patients do not have insurance coverage or their coverage is interrupted, Sanofi Genzyme may be able to help with access to ALPROLIX. Patients may also be able to receive free factor IX for up to 1 year, if needed.

Sanofi Genzyme Support Programs Enrollment Form

*Not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE, or similar federal or state programs including state pharmaceutical assistance programs. Not valid where prohibited by law. Sanofi Genzyme reserves the right to modify or discontinue programs at any time. Savings may vary depending on patients' out-of-pocket costs. All program details provided upon registration.

Patients can manage their hemophilia with the help of MicroHealth tracking

Sanofi Genzyme has joined with MicroHealth in supporting patients and healthcare providers better manage hemophilia.

Learn more.

Hemophilia B Advocacy Groups

This listing is provided as a resource only and does not constitute an endorsement by Sanofi Genzyme of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi Genzyme does not review or control the content of non-Sanofi Genzyme websites. These listings do not constitute an endorsement by Sanofi Genzyme of information provided by any other organizations.

The Coalition for Hemophilia B
National Hemophilia Foundation
Hemophilia Federation of America
World Federation of Hemophilia

Request more information or a meeting with ALPROLIX representativeat the link below.




  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.


  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.


  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.


ALPROLIX® is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.